Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
A video roundup of the week’s top industry news stories.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
Contract Pharma Stream offers a centralized destination where users can watch expert-led sessions anytime, anywhere
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
18655 Krause Street , Riverview, MI, 48193, US
Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the entire drug life cycle. Leveraging an integrated network of facilities in North America, Europe, and India, we provide a comprehensive range of drug discovery services, early phase active pharmaceutical ingredient (API) and formulation development services, and late phase and commercial API and formulation services. We also offer specialized solutions for highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptides, potent solid oral drug products, vaccines, and biologics/bio-therapeutics.
Advances in payload-linker technology have made ADCs a major therapeutic modality, prompting drug developers to strive for greater selectivity and safety in the next wave of ADCs. Payload-linker selection is vital to these initiatives, making the choice of an experienced development and manufacturing partner a key decision in the highly competitive ADC market.
Released By Piramal Pharma Solutions
How Piramal Pharma is shaping resilient, patient-centric development across OSDs, HPAPIs, and sterile injectables.
From discovery to intermediates, APIs & drug products, a CDMO needs expertise across multiple elements of the pharma process to deliver an integrated experience
The acquisition supports Piramal Pharma’s biologics strategy and strengthens its ADCelerate platform.
By: Charlie Sternberg
Adds new spray drying suite with Band 5 containment capacity at its dedicated peptide facility in Turbhe, India.
By: Kristin Brooks
Site has produced hundreds of distinct bioconjugates and supports clinical, commercial, and non‑GMP manufacturing activities.
Enables more flexible and customizable dosing options for critical oral drug therapies, including modified release drug delivery.
The S&P Global CSA analyzes companies on environmental, social, and governance performance, governance maturity, and long-term value creation.
Underscores the facility’s dedication to upholding the highest standards of quality across operations.
Agreement expands Piramal’s payload-linker platform and bioconjugate abilities.
Provides the Morgpeth facility’s Formulation Development Team with an important tool for developing fixed dose combinations and modified release drug delivery.
The U.S. Food and Drug Administration (FDA) approved WIDAPLIK on June 6, 2025.
The investment provides NewAmsterdam Pharma with commercial capacity for a fixed-dose combination of obicetrapib and ezetimibe to meet potential commercial demand.
New benchmark study explores trends and challenges in bioconjugate and ADC development, from linker-payload chemistry to CDMO selection criteria.
Released By Lonza
Chima brings more than 16 years of commercial experience across pharma, biotech and CDMO markets.
Piramal Pharma buys a majority stake in Yapan Bio, and Emergent BioSolutions is restructuring.
By: Patrick Lavery
August Bioservices’ Ryan Downey discusses fill-finish capacity, Annex 1 readiness, technical expertise and the infrastructure needed to move injectable programs toward commercial launch.
Released By August Bioservices
CDMO to manufacture AAV9-GM2 candidate for Tay-Sachs and Sandhoff diseases.
New facilities boost small-molecule API, HPAPI, and ADC payload manufacturing capacity.
Aligning manufacturing capacity with long-term client goals ensures products transition smoothly with consistent performance.
Released By Grand River Aseptic Manufacturing
Join Your Colleagues October 25-28 in New Orleans
Released By AAPS
Fenny brings over two decades of experience across the CDMO and pharmaceutical sectors.
Nearly half of biopharma companies report difficulty finding mammalian production capacity, while cell and gene therapy face even tighter constraints.
By: Katrina Cordovado
The four risks that define successful HPAPI manufacturing.
By: Lidia Garcia Martin
The company may now commence commercial contract manufacturing for CGT products.
Sponsored By Thermo Fisher Scientific Pharma Services
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !
